INHIBITORY EFFECTS OF N-FERULOYLDOPAMINE 143 plays a crucial role as structural proteins on which melanin deposits after production in the presence of MART-1 (9). In summary, our in vitro results show that N-feruloyldopamine, a molecule chosen for its structural analogies with the natural substrates and inhibitors of human tyrosinase, sig- nifi cantly decreased tyrosinase activity in NHEM as well as melanin synthesis in B16 cells. In addition, N-feruloyldopamine has demonstrated interesting antioxidant activity and a signifi cant ability to downregulate Pmel17 gene expression in NHEM, both of which may enhance the melanogenesis inhibition effect. In the absence of cytotoxicity at effi cient concentrations, N-feruloyldopamine represents an interesting alternative to the often-decried kojic acid, hydroquinone, and arbutin. ACKNOWLEDGMENT This work was funded by BASF Beauty Care Solutions France S.A.S. REFERENCES (1) P. J. Matts, B. Fink, K. Grammer, and M. Burquest, Color homogeneity and visual perception of age, health, and attractiveness of female facial skin, J. Am. Acad. Dermatol., 57(6), 977–984 (2007). (2) G. Prota, Regulatory mechanism of melanogenesis: Beyond the tyrosinase concept, J. Invest. Dermatol., 100, 156S–161S (1993). (3) D. S. Kim, S. H. Park, S. B. Kwon, E. S. Park, C. H. Huh, S. W. Youn, and K. C. Park, Sphingosylphos- phorylcholine-induced ERK activation inhibits melanin synthesis in human melanocytes, Pigment Cell Res., 19, 146–153 (2005). (4) H. Ando, H. Kondoh, M. Ichihashi, and V. J. Hearing, Approaches to identify inhibitors of melanin biosynthesis via the quality control of tyrosinase, J. Invest. Dermatol., 27(4), 751–761 (2007). (5) T. Hoashi, J. D. Muller, W. Vieira, F. Rouzaud, K. Kikuchi, K. Tamaki, and V. J. Hearing, The repeat domain of melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fi - bers, J. Biol. Chem., 28(30), 21198–21208 (2006). (6) H. Watanabe, J. C. Valencia, E. Le pape, and Y. Yamaguchi, Involvement of dynein and spectrin with early melanosome transport and melanosomal protein traffi cking, J. Invest. Dermatol., 128, 162–174 (2008). (7) T. Hoashi, H. Watabe, J. D. Muller, Y. Yamaguchi, W. Vieira, and V. J. Hearing, MART-1 is required for the function of the melanosomal matrix protein pmel17/GP100 and the maturation of melanosomes, J. Biol. Chem., 280(14), 14006–14016 (2005). (8) Y. Yamaguchi and V. J. Hearing, Physiological factors that regulate skin pigmentation, Biofactors, 35(2), 193–199 (2009). (9) G. Raposo and M.S. Marks, Melanosomes-dark organelles enlighten endosomal membrane transport, Nat. Rev. Mol. Cell. Biol., 8(10), 786–797 (2007). (10) N. Smit, J. Vicanova, and S. Pavel, The hunt of natural skin whitening agents, Int. J. Mol. Sci., 10, 5326–5349 (2009). (11) K. Maeda and F. M. Arbutin, Mechanism of its depigmenting action in human melanocytes culture, J. Pharmacol. Exp. Ther., 276(2), 765–769 (1996). (12) O. Nerya, J. Vaya, R. Musa, S. Izrael, R. Ben-Arie, and S. Tamir, Glabrene and isoliquiritigenin as tyrosinase inhibitors from licorice roots, J. Agric. Food Chem., 51(5), 1201–1207 (2003). (13) A. Khemis, A. Kajafa, C. Queille-Roussel, L. Duteil, and J. P. Ortonne, Evaluation of effi cacy and safety of rucinol serum in patients with melasma: A randomized controlled trial, Br. J. Dermatol., 156(5), 997–1004 (2007). (14) A. Greatens, T. Hakozaki, A. Koshoffer, H. Epstein, S. Schwemberger, G. Babcock, et al., Effective in- hibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible, Exp. Dermatol., 14(7), 498–508 (2005). (15) S. Okombi, D. Rival, S. Bonnet, A. M. Mariotte, E. Perrier, and A. Boumendjel, Discovery of benzyli- denebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes, J. Med. Chem., 49(1), 329–333 (2006).

JOURNAL OF COSMETIC SCIENCE 144 (16) C. Olivares and F. Solano, New insights into the active site structure and catalytic mechanism of tyrosinase and its related proteins, Pigment Cell Melanoma Res., 22, 750–760 (2009). (17) Y. Matoba, T. Kumagai, A. Yamamoto, H. Yoshitsu, and M. Sugiyama, Crystallographic evidence that the dinuclear copper center of tyrosinase is fl exible during catalysis, J. Biol. Chem., 281(13), 8981–8990 (2006). (18) S. Khatib, O. Nerya, R. Musa, S. Tamir, T. Peter, and J. Vaya, Enhanced substituted resorcinol hydro- phobicity augments tyrosinase inhibition potency, J. Med. Chem., 50, 2676–2681 (2007). (19) S. Okombi, D. Rival, S. Bonnet, A. Mariotte, E. Perrier, A. Boumendjel, Analogues of N-hydroxycin- namoylphenylalkylamides as inhibitor of human melanocytes tyrosinase, Bioorg. Med. Chem. Lett., 16, 2252–2255 (2006). (20) C. Gederman, C. Eicken, B. Krebs, Structure of catechol oxydase: New insight into the function of type-3 copper proteins, Acc. Chem. Res., 35, 183–191 (2002). (21) A. J. Winder and H. Harris, New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase, Eur. J. Biochem., 198(2), 317–326 (1991). (22) A. El-Gamal, Studies on the chemical constituents of Atraphaxis spinosa L. var. sinaica Boiss, Nat. Med., 48(4), 304–306 (1994). (23) S. Mi An, J. S. Koh, and Y. C. Boo, p-Coumaric acid not only inhibits human tyrosinase activity in vitro but also melanogenesis in cells exposed to UVB, Phytother. Res., 24, 1175–1180 (2010). (24) S. Matsuda, H. Shibayama, M. Hisama, M. Ohtsuki, and M. Iwaki, Inhibitory effects of a novel ascorbic derivative, disodium isostearyl 2-O-L-ascorbyl phosphate on melanogenesis, Chem. Pharm. Bull., 56(3), 292–297 (2008). (25) H. Ando, M. S. Matsui, and M. Ichihashi, Quasi-drugs developed in Japan for the prevention or treat- ment of hyperpigmentary disorders, Int. J. Mol. Sci., 11, 2566–2575 (2010). (26) L. G. Chen, W. L. Chang, C. J. Lee, L. T. Lee, C. M. Shih, and C. C. Wang, Melanogenesis inhibition by gallotannins from Chinese Galls in B16 mouse melanoma cell, Biol. Pharm. Bull., 32(8), 1447–1452 (2009). (27) J. Ancans, D. J. Tobin, M. J. Hoogduijn, N. P. Smit, K. Wakamatsu, and A. J. Thody, Melanosomal pH controls rate of melanogenesis Eumelanin/Phaeomelanin ratio and melanosome maturation in melano- cytes and melanoma cells, Exp. Cell. Res., 268, 26–35 (2001).